Document Detail


Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin.
MedLine Citation:
PMID:  17414408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.
Authors:
Roberto P Santos; Pablo J Sánchez; Asuncion Mejias; Daniel K Benjamin; Thomas J Walsh; Sanjay Patel; Hasan S Jafri
Related Documents :
19839958 - Management of isolated rectal bleeding in newborn infants: comparison of two time periods.
10530848 - The use of ultrasound in determining the initiation of treatment in instability of the ...
6244378 - The effect of acth therapy upon infantile spasms.
23869958 - Psychometrics of the neonatal oral motor assessment scale.
14599038 - Influence of different types of post-discharge feeding on somatic growth, cognitive dev...
20525358 - Predictors of positive blood culture and deaths among neonates with suspected neonatal ...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  The Pediatric infectious disease journal     Volume:  26     ISSN:  0891-3668     ISO Abbreviation:  Pediatr. Infect. Dis. J.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-04-06     Completed Date:  2007-06-05     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8701858     Medline TA:  Pediatr Infect Dis J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  364-6     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX 75390-9063, USA. roberto.santos@UTSouthwestern.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amphotericin B / therapeutic use
Antifungal Agents / therapeutic use*
Aspergillosis / drug therapy*,  microbiology
Dermatomycoses / drug therapy*,  microbiology
Echinocandins
Humans
Infant, Extremely Low Birth Weight
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases / drug therapy*,  microbiology
Lipopeptides
Lipoproteins / therapeutic use
Peptides, Cyclic / therapeutic use
Pyrimidines / therapeutic use
Treatment Outcome
Triazoles / therapeutic use
Grant Support
ID/Acronym/Agency:
1U10-HD45962-02/HD/NICHD NIH HHS; HD046000/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Antifungal Agents; 0/Echinocandins; 0/Lipopeptides; 0/Lipoproteins; 0/Peptides, Cyclic; 0/Pyrimidines; 0/Triazoles; 0/liposomal amphotericin B; 0/micafungin; 0/voriconazole; 1397-89-3/Amphotericin B

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immu...
Next Document:  A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis.